Last reviewed 2026-04-20 · How we verify

Zenapax (DACLIZUMAB)

Zenapax (DACLIZUMAB) is a monoclonal antibody developed by HOFFMAN-LA ROCHE, targeting the Interleukin-2 receptor. It is classified as an Interleukin-2 Receptor Blocking Antibody, used to treat relapsing remitting multiple sclerosis and renal transplant rejection. The drug is still owned by HOFFMAN-LA ROCHE and has been FDA approved since 1997. Key safety considerations include its potential to increase the risk of infections and malignancies. Commercially, the status of Zenapax is patented.

At a glance

Approved indications

• Relapsing remitting multiple sclerosis
• Renal transplant rejection

Common side effects

No common side effects on file.

Key clinical trials

• Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen (PHASE1)
• Prescription Drug Safety and Effectiveness in Multiple Sclerosis
• LMB-2 to Treat Hairy Cell Leukemia (PHASE2)
• Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation (PHASE4)
• Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols (PHASE4)
• Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation (PHASE4)
• Phase I/II Thymus Transplantation With Immunosuppression #950 (PHASE1,PHASE2)
• Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma (PHASE1,PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.